RET and cancer: As regards RET-positive cancers, RET gatekeeper mutations at the V804 residue (V804L and V804M) primarily occur as germline mutations in sporadic medullary thyroid cancers and in about 2% of MEN2 where they act as primary driver mutations and cause intrinsic resistance to several MKIs [94].